Quantum-Structural Disease Modeling

• Quantum-structural disease modeling is an interdisciplinary method integrating quantum mechanics and structural biology to predict phenotypic outcomes of genetic mutations.
• It combines ab initio quantum calculations, AlphaFold-derived structures, and VQE-based energy scans to compute metrics like the Relative Quantum Activity Score (RQAS).
• The framework identifies quantum cliffs where minimal sub-ångstrom shifts in enzyme active sites, as seen in RPE65, directly correlate with clinical disease severity.

Quantum-structural disease modeling is an emerging interdisciplinary framework that integrates quantum mechanical analysis of enzyme active sites with atomic-resolution structural biology to predict phenotypic outcomes of genetic mutations. This paradigm addresses the longstanding challenge of mapping sub-atomic perturbations in protein structure directly to clinical severity, bypassing many limitations of sequence- or classical structure-based models. The approach is exemplified by studies of the RPE65 isomerohydrolase in retinal disease, where pathogenesis is governed by quantum-tunneling thresholds at the active site. Recent work demonstrates that quantum effects, particularly proton tunneling rates, can serve as actionable mechanistic biomarkers, providing an exponential sensitivity to minimal geometric changes and establishing a predictive genotype-structure–phenotype link (Ghoshal et al., 26 Jan 2026).

1. Theoretical Foundations and Scope

Quantum-structural disease modeling is predicated on the realization that, for certain enzymes, catalytic activity is fundamentally constrained by quantum mechanical phenomena—most notably, proton tunneling across energy barriers defined by active-site geometry. This approach stands in contrast to classical molecular mechanics, which cannot account for non-classical transmission probabilities that decay exponentially with atomic separation.

The paradigm encompasses:

• The use of quantum chemistry—specifically, ab initio electronic structure methods—to compute energy barriers and transmission probabilities for elementary steps such as proton-coupled electron transfer.
• The reduction of structural perturbations (such as those induced by missense variants) to shifts in geometrical parameters that directly affect quantum transmission.
• The establishment of quantum-derived metrics that can be mapped to biochemical activity and clinical outcome.

This framework is broadly applicable to pathogenic processes where the rate-limiting step is quantum-mechanically sensitive, fundamentally altering the interpretation of genotype–phenotype correlations.

2. Structure-to-Phenotype Computational Pipeline

The structure-to-phenotype pipeline described in (Ghoshal et al., 26 Jan 2026) is a hybrid quantum-classical workflow enabling the in silico prediction of disease severity from a given amino acid variant. The critical components are:

• Input variant structures are generated using AlphaFold2, coupled with a targeted structural perturbation model to explore the local geometric impact of point mutations at the active site.
• The key geometric order parameter is the donor–acceptor O–O distance, $d_{OO}$, at the proton transfer site.
• The potential energy surface (PES) along the proton coordinate is computed via Variational Quantum Eigensolver (VQE) scans, discretizing the proton path across 25 positions between the two oxygens.
• From the PES $E_0(z)$, the maximum defines the effective barrier height $V_0$, and the barrier width is $w = d_{OO} - 1.9$ Å.
• Quantum (WKB) and classical (Boltzmann) transmission probabilities are calculated, yielding a total transfer probability for the mutant and wild-type systems.
• The Relative Quantum Activity Score (RQAS) is then computed as a dimensionless metric quantifying relative catalytic competence.

The following table summarizes computational and structural descriptors central to the workflow:

Parameter	Definition	Computational Source
$d_{OO}$	Donor–acceptor O–O separation ($\rm \AA$)	AlphaFold2 + perturbation
$V_0$	Barrier height (kcal/mol or J)	VQE PES maximum
$w$	Effective barrier width ($d_{OO}-1.9$ $\rm \AA$)	Derived from structure
$P_{\rm tunnel}$	Quantum transmission probability	WKB approximation
$P_{\rm thermal}$	Classical over-the-barrier probability	Boltzmann factor
RQAS	Ratio of total transfer probabilities	Computed per below

3. Mathematical Formalism: The Relative Quantum Activity Score (RQAS)

The central quantitative construct in quantum-structural disease modeling is the RQAS, defined as

$$\mathrm{RQAS} = \frac{P_{\mathrm{total}}^{(\text{mutant})}}{P_{\mathrm{total}}^{(\mathrm{WT})}}, \quad RQAS \in (0, 1]$$

with

$$P_{\mathrm{total}} = P_{\mathrm{tunnel}} + P_{\mathrm{thermal}}$$

$P_{\mathrm{tunnel}}$ (tunneling) is evaluated using the WKB approximation:

$$P_{\mathrm{tunnel}} = \exp\bigl(-2 w \kappa\bigr), \qquad \kappa = \frac{\sqrt{2\mu V_0}}{\hbar}$$

• $w = d_{OO} - 1.9$ Å (barrier width)
• $\mu = 1.6726 \times 10^{-27}$ kg (proton mass)
• $\hbar = 1.054 \times 10^{-34}$ J·s
• $V_0$ from the computed barrier height

$P_{\mathrm{thermal}}$ (classical, over-the-barrier) is:

$$P_{\mathrm{thermal}} = \exp\left(-\frac{V_0}{k_B T}\right)$$

• $k_B = 1.381 \times 10^{-23}$ J/K
• $T = 310$ K

Computational steps:

• For each variant, $d_{OO}$ is obtained from AlphaFold + mutation modeling.
• VQE yields $V_0$ from the PES maximum.
• WKB and Boltzmann equations produce $P_{\mathrm{tunnel}}$ and $P_{\mathrm{thermal}}$.
• $P_{\mathrm{total}}$ is computed and normalized to wild-type.

RQAS has the following properties:

• $RQAS=1$ for wild-type
• $RQAS\ll1$ for mutants with reduced activity
• $RQAS\to0$ for extremely compromising mutations

No alternative normalization or Boltzmann-only/ $-\ln$ forms are used; RQAS is strictly a ratio of total probabilities.

4. Quantum Sensitivity and the "Quantum Cliff" Threshold

Quantum-structural disease modeling reveals an exponential sensitivity of proton transfer to sub-Angstrom geometric variation. In the one-dimensional O–H–O potential, tunneling transmission decays as $P_{\mathrm{tunnel}} \propto \exp(-2w\kappa)$, such that increments in $d_{OO}$ of the order of 0.1 Å can drop the transmission probability by many orders of magnitude. By normalizing to the wild-type, RQAS directly quantifies this geometry-controlled "quantum cliff," a non-linear regime where sub-critical structural perturbations abruptly inactivate the enzyme.

Key numerical cutoffs from (Ghoshal et al., 26 Jan 2026):

Variant	$d_{OO}$ (Å)	RQAS	Clinical Severity
WT	2.70	$1.00$	Healthy
T457N	2.78	$3.5 \times 10^{-10}$	Mildest mutant
L341S	2.85	$1.5 \times 10^{-18}$	Moderate
Y368H	2.98	$2.6 \times 10^{-34}$	Severe
H241R	3.35	$1.6 \times 10^{-85}$	Null/Blind

A threshold for clinical blindness appears at $d_{OO} \approx 3.0$ Å ($RQAS \approx 10^{-34}$). In practice, $\Delta d > 0.10$ Å (i.e., $d_{OO}>2.80$ Å, $RQAS<10^{-18}$) is associated with severe phenotypes.

The modeling incorporates one-dimensional, static potential assumptions (rectangular-barrier WKB) and does not include phonon-assisted/dynamical fluctuations—factors that may modulate quantum transmission in vivo but do not dominate the observed activity cliff.

5. Clinical Interpretation and Biomarker Utility

RQAS provides a quantum-mechanistic biomarker for clinical stratification of RPE65 mutations:

• RQAS near unity indicates quantum-efficient proton transfer and retained enzymatic activity.
• RQAS well below unity reflects the enzyme's transition across the quantum cliff, corresponding to substantial or catastrophic loss of function.
• An RQAS threshold $>10^{-10}$ predicts mild (e.g., night-blindness) phenotypes; $<10^{-18}$ predicts early-onset Leber Congenital Amaurosis (LCA).

The entire assessment is performed in silico, using only protein sequence, structure prediction, and quantum PES scanning, obviating the need for enzyme purification or kinetic assays. This enables high-throughput, mechanism-driven variant effect prediction and stratification in clinical genetics.

6. Significance and Broader Implications

The quantum-structural modeling framework establishes, for the first time, a quantitative, predictive, and mechanistic connection between atomic-level geometry and macroscopic disease severity in a clinically relevant enzyme. By demonstrating that the RPE65 enzyme operates near a quantum-critical point—where minute structural changes drive discontinuous functional transitions—this approach redefines the landscape of actionable biomarkers in molecular medicine.

A plausible implication is that other enzyme systems, particularly those involving proton-coupled electron transfer or hydrogen tunneling, may exhibit similar quantum cliffs, motivating extension of the RQAS methodology. The generalizability of this framework positions quantum-structural modeling as a cornerstone for future predictive molecular pathology and precision medicine (Ghoshal et al., 26 Jan 2026).